General Public

This information sheet discusses the bacille Calmette-Guerin (BCG) vaccine for TB disease, which is used in many countries to prevent childhood tuberculous meningitis and miliary disease. It explains why the BCG is not generally recommended for use in the United States; suggests that the BCG should be considered under specific circumstances; and provides recommendations for when the BCG should be used with children and health care workers and contraindications when it should not be used, such as for immunosuppressed persons and pregnant women.

This fact sheet discusses TB and how it is affected by the HIV. It defines TB and explains the difference between TB infection and latent TB infection. The fact sheet advises that HIV weakens the immune system increasing the chance that in people with HIV and latent TB, the TB germs will become active and attack the body causing TB disease. It emphasizes the importance of TB treatment and taking the TB drugs as prescribed.

This information sheet discusses TB and the risk for international travelers. It explains TB transmission, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of the disease, and how drug resistance occurs. The information sheet considers whether international travelers are at risk of MDR or XDR TB while traveling, the risk of acquiring TB on an airplane, how TB can be prevented, TB vaccine, and what an individual should do before traveling internationally and if an individual thinks that he/she may have been exposed to someone with TB disease.

This information sheet explains TB for employers in non-healthcare settings. It describes TB disease, latent TB infection (LTBI), active TB, how it is determined whether a patient has active TB or LTBI, the symptoms of TB, what one should do if an employee reports having positive TB or has been in contact with someone with TB, and what happens after the employer contacts the local or state TB program.

This information sheet discusses treatment for latent TB infection. It reminds patients to keep their weekly medical visits, explains directly observed therapy, provides a list of items to discuss with their doctor, a medication schedule, and advises them to call the doctor immediately if they experience any of the side effects on the list. The information sheet also includes space for the doctor's and clinic's name and telephone number.

This information sheet discusses the once-a-week 12-week treatment of rifapentine and isoniazid for latent TB infection (LTBI). It explains LTBI, why it is necessary to treat it, the treatment plan and how it is managed, and a chart for tracking. It also includes hints on how to take the medicine including eating before taking it and avoiding alcohol, and describes normal side effects and possible problems including which signs and symptoms require you to call the doctor or nurse and what to do when taking a dose of medicine in the absence of medical staff.